Immunovant (IMVT) reported earnings 30 days ago. What's next for the stock?
Immunovant (IMVT) declines 5% on dismal fourth-quarter fiscal 2024 results. The company names IMVT-1402 as its new lead candidate to initiate several studies for autoimmune indications.
Biohaven stock crashed Wednesday after the company's experimental protein-degrading drug lagged investor expectations.